MIM
MDGL icon

Monashee Investment Management’s Madrigal Pharmaceuticals MDGL Stock Holding History

Monashee Investment Management’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-15,000
Closed -$2.19M – 70
2023
Q3 		$2.19M Buy
+15,000
New +$2.82M 0.92% 41
2018
Q2 		– Hold
0
– – – 95
2017
Q4 		– Hold
0
– – – 47

Other funds holding MDGL

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Monashee Investment Management's MDGL Position: Q4 2023 in Review

Monashee Investment Management sold out of Madrigal Pharmaceuticals (MDGL) in Q4 2023, closing a stake of 15,000 shares — an estimated $2.19M sold.

Monashee Investment Management first reported a position in MDGL in Q3 2023 and held it in 1 quarter. The position peaked at $2.19M in Q3 2023. 226 funds tracked by Wall St. Rank hold MDGL as of Q4 2023.

  • Monashee Investment Management reported no remaining Madrigal Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Monashee Investment Management sold 15,000 Madrigal Pharmaceuticals shares in Q4 2023, an estimated $2.19M.
  • Monashee Investment Management first reported a position in Madrigal Pharmaceuticals in Q3 2023 and held it in 1 quarter.
  • Monashee Investment Management's Madrigal Pharmaceuticals position peaked at $2.19M in Q3 2023.
  • 226 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q4 2023.

Based on Monashee Investment Management's 13F filing for Q4 2023, filed 12 Feb 2024.